Introduction {#Sec1}
============

Historical Background {#Sec2}
---------------------

Reye's Syndrome (RS) was first documented by Douglas Reye and colleagues in 1963 as an "encephalopathy with fatty degeneration of the viscera," a rare entity, but one that at that time was associated with an 80% mortality rate ([@CR56]). Although the apparent incidence and outcome of the disease have improved, it continues to be one of the major causes of noninflammatory neurologic death after a viral illness in children ([@CR67]; [@CR34]).

General Features of the Human Disease {#Sec3}
-------------------------------------

Reye's Syndrome is defined clinically as a nonspecific encephalopathy with fatty visceromegaly that has a biphasic course. The first phase of the disease is typically a mild, unremarkable viral illness, frequently influenza B or varicella. The second phase begins when the child is beginning to recover from the viral illness, and is associated with profuse and persistent vomiting. Behavioral changes, including lethargy, confusion, and combativeness can rapidly (within 4--60 h) progress to stupor, coma, and death.

Morphological and biochemical findings have led many to speculate that the primary insult in RS is an acute, self-limiting disturbance in hepatic mitochondrial structure and function ([@CR41]; [@CR45]). There is a characteristic reduction in the numbers of liver rnitochondria. Those present are swollen dramatically with ultrastructural loss of their matrices and cristae ([@CR14]). However, there is no evidence of cellular necrosis, and the mitochondrial distortions are completely reversed upon recovery from the disease. The biochemical changes are also indicative of a mitochondrial disease, since the metabolic pathways that are affected (urea cycle, gluconeogenesis, fatty acid oxidation) are localized either in whole or part in the mitochondria (for review, *see* [@CR1]). At least some products of the blockade of these pathways (e.g., ammonia, fatty acids) are potential neurotoxins, and have been implicated strongly in the encephalopathic phase of the disease. Serum ammonia levels are extremely high during the early course of the disease, and in some cases have been reported to be 60- fold higher than normal levels ([@CR69]). ([@CR74]) recently reported that serum levels of both monocarboxylic and dicarboxylic fatty acids are elevated at certain stages of the disease. There is also evidence that the relative proportions of unesterified polyunsaturated fatty acids are increased in serum ([@CR51]) and in erythrocytes ([@CR62]) of RS patients. Contiguous with serum lipid abnormalities, the cells of the visceral organs, particularly the liver, are loaded with fat that is stored as microvesicular droplets ([@CR1]). This may be closely associated with a loss of regulation of adipose tissue lipolysis ([@CR37]) and an increased uptake of fatty acids by the liver. Abnormalities in carbohydrate metabolism have been inferred from amino acid profiles ([@CR60]) and depletion of hepatic glycogen ([@CR1]). In spite of this generalized mitochondrial malfunction, cytosolic enzyme activity is normal in RS patients. Moreover, the hepatomegaly alone does not appear to explain the deaths of the children, as the liver is often recovering while the brain continues to deteriorate.

The Centers for Disease Control (CDC) have set the following clinical and pathological criteria for a diagnosis of RS: Acute, noninflammatory encephalopathy with cerebral spinal fluid (CSF) containing less than eight white blood cells/ mm^3^ and histological sections of the brain demonstrating cerebral edema without meningeal or perivascular inflammation;Fatty metamorphosis of the liver by biopsy or necropsy;Serum glutamic oxaloacetic transaminase (SGOT) levels greater than 3X normal, or blood ammonia levels greater than 1.5X normal; andNo other explanation for the neurologic or hepatic abnormalities. ([@CR30]) have suggested that the diagnostic criteria of the CDC be reassessed, as it is now believed that Reye's Syndrome may actually be two distinct disease entities, with the infantile form (i.e., in children less than 2--3 yr of age) attributable to the unmasking of an inborn error of metabolism, a group of diseases that include the organic acidemias, urea cycle defects, and medium-chain acyl-CoA dehydrogenase deficiency (MCAD) ([@CR70]; [@CR32]; [@CR58]). The "unmasking" may be a response to a specific illness, or to any disorder that limits caloric intake, and results in a disease that in many ways resembles RS. Factors that may distinguish inborn errors from RS include normal ammonia levels at presentation, a very short period between onset of initiating illness and pernicious vomiting, and lack of signs of increased intracranial pressure.

Encephalopathy of RS {#Sec4}
====================

Neuropathology {#Sec5}
--------------

The encephalopathy of Reye's Syndrome is a noninflammatory, reversible process. Death, if it occurs, is usually owing to a severe brain edema in which the cerebral cortex has swollen to the extent that it becomes necrotic up against the nonyielding cranial vault ([@CR80]). The swelling leads to increased intracranial pressure and altered cerebral perfusion ([@CR44]; [@CR29]). It is not known whether the edema is cytotoxic or vasogenic. The extensive histopathological studies of ([@CR52]) and others ([@CR80]) have shown that there is an increase in the number and size of astrocytes, and that they are often devoid of glycogen granules. Of particular interest is the fact that astrocytic mitochondria are relatively normal in structure. Depending on the severity of the disease, neurons may also be enlarged, and in contrast to the astrocytes, may contain pale, enlarged, and pleomorphic mitochondria. Capillary endothelial cells appear to be normal, with normal-appearing mitochondria, which is consistent with evidence that the blood-brain barrier is intact ([@CR1]). Demyelination does not appear to occur, although ([@CR52]) have reported the presence of watery blebs within the myelin sheaths,

Biochemical Abnormalities {#Sec6}
-------------------------

Relatively little is known regarding the biochemical pathology of the brain in RS. There are no outstanding abnormalities in lipid accumulation or metabolism ([@CR1]), and the activities of enzymes that are altered in the liver appear to be normal ([@CR57]). Simultaneous measurements of arterial and jugular vein ammonia levels indicate that the toxic metabolite is taken up in large quantities by the brain in RS patients. The excessive load of ammonia appears to be related to increased brain lactic acid production (for review, *see* [@CR20]). ([@CR28]) have demonstrated hypercatecholaminemia in patients with RS, and suggested that this might contribute to the encephalopathy of the disease. A recent report also indicated that CSF levels of neuron-specific enolase (NSE), a prominent neuronal cytosolic enzyme that is released upon neuronal destruction, are elevated in RS ([@CR49]).

The Etiology of RS: Theories {#Sec7}
============================

In spite of our increasing understanding of the metabolic abnormalities in RS, its etiopathogenesis remains obscure ([@CR16]); [@CR48]. In the following brief discussion, the prominent theories regarding the etiology of RS can be divided into two categories: those pertaining to the initiation of the disease process, and those concerning the events related specifically to the development of encephalopathy.

One of the consistent features of RS is that its development is associated with an antecedent viral illness involving one of several specific infecting organisms. However, since Reye's original publication in 1963, many investigators and clinicians have believed that a toxin is involved in some manner in the initiation of the disease, based on the fact that its progression resembles an acute toxic event. A wide range of exogenous toxins have been shown to produce at least some of the clinical features of RS ([@CR53]); however, no single xenobiotic toxin or groups of toxins have been shown unequivocally to be the causative agent(s) ([@CR9],[@CR12]). Within the past several years, considerable attention has focused on salicylates as a causative agent, and declines in aspirin use and in the incidence of RS tend to support an association between the two. However, attempts to demonstrate salicylate-dependent potentiation of viral effects in animal models generally have been unsuccessful (*see* Section 4.5.2.). In the human disease, there is no obvious genetic predisposition, and in cases involving siblings, one might presume that the RS-like disorder is actually an inborn error of metabolism (*see* Section 1.2.). Many investigators, including ourselves, now believe that exposure of susceptible individuals to environmental chemicals, including salicylates, can result in an abnormal and potentially lethal response to what is normally a relatively benign virus infection ([@CR9]).

There are few who would dispute that RS is a mitochondrial disease in which there are dramatic alterations in metabolism that result in production of high levels of otherwise normal metabolites. One of the primary focuses in RS research has been to determine which, if any, of these metabolites are responsible for the distinct encephalopathy of the disease. The three groups of metabolites that have been deemed the most likely candidates include ammonia, free fatty acids, and short chain organic acids, each of which is known to produce neuropathy in humans when present in excessive amounts ([@CR20]). A broad discussion of this topic is beyond the scope of this review, but it should be mentioned that for each of these groups there is substantial evidence against their being the sole encephalopathic factors in RS. Nevertheless, several working hypotheses have evolved from the knowledge that individuals with RS are in a highly exaggerated catabolic state, and these have provided the basis for the development of several of the animal models described in this chapter.

Animal Models of RS {#Sec8}
===================

It is believed that the only way we are going to elucidate the causes of the encephalopathy in RS is to determine the sequence of events that occurs during the pathogenic process. This question is virtually impossible to address in patients, since the initiating events, and many of their biochemical consequences, hav e taken place (and may have reverted to normal) before the disease is diagnosed. The only way we can hope to understand the process is through the development of animal models that mimic the disease.

Although a variety of different approaches has been used to develop a suitable animal model for RS, it is generally accepted that no single model fulfills all of the criteria of the human disease ([@CR25]; [@CR24]; [@CR34]). In some cases, the models have not yet been characterized completely, whereas in others, there is an apparent inability to reproduce a specific effect. The latter may be owing to the transient nature of many of the biochemical/morphological changes associated with this multifactorial disease. In the following sections, we shall describe the experimental protocols for the most widely used animal models of RS. We shall also indicate briefly which of the features of the human disease they successfully mimic, and some of the problems associated with each. The models have been divided into three groups, based on whether they involve toxin alone, virus alone, or a combination of toxin and virus. Data regarding the serum and liver changes, and the encephalopathy that occurs in each of the models is presented in [Tables 1](#Tab1){ref-type="table"}--[Tables 3](#Tab3){ref-type="table"}. Table 1Serum Abnormalities in Animal Models and in Human Reye's SyndromeTransaminasesHyperammonemiaSGOTSGPTacidemiaacidemiaHuman RS+↑↓→±±+Cracker, 1982 Brown and Forman, 1982Animal modelsAflatoxin monkeysND^1^↑↑++NDBourgeois et al., 19714\''-Pentenoate rats+↑**→**ND--,↓± (fasting dependent)+Glasgow & Chase, 1975; Thayer, 1984; Hart et al., 1989Margosa Oil rats+↑↑ND+NDSinniah et al., 1985Octanoate infusion rabbits infusion+→ND+--NDTrauner, 1982 PUFARabbitsND↑NDND(--)^2^NDKang etal., 1982Concentrated FluB mice+↑ND+?NDDavis, 1986Endotoxin rats+→→+--NDYoder et al., 1985Hyperammonemia/FluBFerretsArg Diet+↑ND+-(↑)NDDeshmukh etal.,1982;Arg Diet+DeshmukhFluBetal.,1983+↑ND+NDNDDeshmukh andThomas, 1985Arg Diet +FluB + ASA+ +↑↑ND+NDNDSurfactant/FluBMiceSurfactant+NDND-NDNDCracker et al.,1986Surfactant +FluB+NDND- NDND^1\ ND,\ not\ done\ or\ not\ reported,\ 2\ (),\ moderate\ changes^ Table 2**Serum Abnormalities in Animal Models and in Human Reye's Syndrome**Liver enzyme activities^1^Fatty liverMitochondrial swelling and degenerationOTCCPSMAOCATGDHGlycogen depletionInflammation and necrosisReferencesHuman RS++↓↓↓→↓+\_Cracker, 1982; Brown and Forman, 1982; Mitchell et al.,1985Animal modelsAflatoxinMonkeys+ND^2^NDNDNDNDND++Bourgeois etal.,1971RatsNDND↓↓NDNDNDND+ (necrosis)Thurlow et al., 19804-PentenoateRats+ (fasting dependent)±NDNDNDND↓ND-Glasgow and Chase, 1984; Thayer, 1984; Hart etal., 1989Margosa oilRats++NDND→↓→+-Sinniah et al., 1985OctanoateRabbits++NDNDNDNDNDND-Trauner,1982ConcentratedMice+--↓NDNDNDND(+)-Davis, 1986Spontaneous RS?Mice++NDNDNDNDND+-Browenstein etal.,1984Endotoxin Rats++NDNDNDNDND+---Yoder et al.,1985Hyperammonemia/ FluBFerrets Arg-diet+ND→→NDNDNDNDNDDeshmukhet al, 1982,1983;Deshtnukhand Thomas, 1985Arg diet + FluB+ND↓→NDNDNDNDNDArgr diet + FluB + ASA++↓↓↓NDNDND+NDsurfactant/FluB MiceToximul------→NDNDNDNDND---Cracker etal., 1986Toximul + FluB---+↓NDNDNDNDND---Toximul+ EMC++↓NDNDNDNDND---Taylor et al., 1979Atlox + EMC±+↓→NDNDND+---Hug et al., 1981^1^Abbreviations of enzyme activities- OTC, ornithine transcarbamylase; CPS, carbamyl phosphate synthetase; MAO, monoamine oxidase, CAT, catalase; GDH, glutamate dehydrogenase. ^2^ND, not done or not reported. Table 3**The Encephalopathy of Human Rs and in Animal Models**ConvulsionsComaEdemaElevated ICPconingAstrocytic swellingAstrocyte proliferationNeuronal degenerationReferencesHuman RS++++++?+Partin et al,1985Crocker, 1982Ammal modelsAflatoxin Monkeys±(2/8)++(8/8)ND^1^±(2/8)NDND+(8/9)Bourgeols et al.,19714-Pentenoate Rats++NDNDNDNDNDNDGlasgow and chase, 1975;Hart et al., 1989Margosa oil Rats++−NDNDNDNDNDSinnah et al.,1985Octanoate infusion Rabbits±(1/3)+−+ND(+)ND(+)Trauner, 1982;Trauner and Adams, 1981PUFA infusion Rabbits++NDNDNDNDNDNDKang et al., 1982Concentrated FluB Mice++(+)NDNDNDNDNDDavis, 1986Spontaneous RS? Mice−+?NDND+++Brownstein et al,1984**FerretsArg diet+++(CE)** ^**2**^**NDNDNDNDNDDeshmukhet al.,1982**;**Arg diet +DeshmukhFluB+++(CE)NDNDNDNDNDandThomas**,**1985Arg diet +FluB + ASA+++(CE)NDNDNDNDNDSurfactant/FluBMiceToximul**−−**ND**−**NDNDNDNDCrccker etal.,1986Toximul +FluB**±±**ND+NDNDNDND**^**1**^ **ND, not done or not reported; 2CE, choroid plexus epithelial cells.**

Models Associated with Environmental Toxins {#Sec9}
-------------------------------------------

Many attempts to establish animal models of RS on the basis of exposure to an environmental chemical (with or without virus infection) have evolved from epidemiological findings, some of which were regional in nature. A variety of xenobiotic substances have been tested ([@CR4]; [@CR8]; [@CR35]; [@CR9]), and the results have led to the establishment of models that involve exposure to aflatoxin ([@CR2]; [@CR73]), 4-pentenoic acid ([@CR31]; [@CR72]; [@CR33]), surfactants ([@CR6]; [@CR61]; [@CR35]; [@CR11]), and salicylates ([@CR42]; [@CR21]).

### Aflatoxin {#Sec10}

Aflatoxin B~1′~, a toxic metabolite of *Aspergillus flavus*, was suggested as a candidate in the pathogenesis of RS based on the high incidence of encephalopathy and fatty degeneration of the viscera in Thai children, and on the recognized presence of the toxigenic fungi in many local food products, including rice. Two animal models have been based on aflatoxin toxicity: the monkey model of ([@CR2]), and the rat model of ([@CR73]).

The Bourgeois model involves the use of female, crab-eating macaque monkeys (*Macaca fasicularis*) between 36 and 44 mo of age (average body wt, 1.7 kg), that are maintained on a primate diet supplemented with fruit. For the experiment, the animals are divided into six groups (4 macaques/group), each of which is fed a different concentration (0--40.5 mg/kg) of aflatoxin B~1~ in single-dose gelatin capsules. On the day the toxin is given, the animals are kept under constant observation and blood samples are collected at regular intervals. Bourgeois and coworkers reported that animals that receive ≥13.5 mg/kg begin to die 67 h following aflatoxin administration, and all are dead by 149 h.

The most consistent clinical finding with this model is vomiting, which occurs in all animals that die. The animals that receive fatal doses go through a period of lethargy and depression prior to coma; however, a relatively small proportion experience convulsions. The encephalopathy is associated with increased ratios of brain:body weights, cerebral edema, swelling and separation of the myelin sheath, gliosis, and neuronal degeneration. The latter is manifested by shrinkage and increased eosinophilia of the cytoplasm, pyknosis and distortion of the nuclei, and satellitosis. Systemically, significant serum changes include hypoglycemia, increased free fatty acids and transaminase activities, and decreased phospholipids. There is fatty infiltration of the visceral organs, including the liver, kidneys, and heart.

The rat model described by ([@CR73]) involves administering a single dose of aflatoxin B~1~ (3 mg/kg, in dimethylsulfoxide or saline) to male Fischer rats (120--150 g). The animals are killed 2 or 24 h after treatment. The only information available regarding the effects of this treatment is that at 24 h, there are significant reductions in activity of the hepatic enzymes, carbamyl phosphate synthetase (US) and ornithine transcarbamylase (OTC) (40 and 30% inhibition, respectively).

One of the main criticisms of the theory that aflatoxin plays a role in the etiology of RS is that investigators have failed to confirm the presence of high levels of the toxin in livers of many patients who presumably died of the disease ([@CR59]).

### 4-Pentenoic Acid (Hypoglycin) {#Sec11}

Jamaican Vomiting Sickness is an RS-like disease that is believed to be caused by ingestion of hypoglycin, a toxic component of unripe akee fruit ([@CR68]). On the basis that the two diseases might share a common pathogenesis, an animal model was established using 4-pentenoic acid, a structural analog of hypoglycin ([@CR31]; [@CR72]; [@CR33]).

In the most recently described 4-pentenoic acid model ([@CR33]), adult male Sprague-Dawley rats (200--300 g) are given ten sc injections over the course of 3 d with purified 4-pentenoic acid (12.5 mg/kg, neutralized to pH 7.4) (chronic phase). A final dose (200 mg/kg) (acute phase) is administered 30 min before killing the animals. This model has been varied by other investigators with respect to dosage, route of administration (e.g., sc vs ip), chronic vs acute treatment, and fed vs fasted animals. The variability in the results obtained may well reflect these differences.

Rats injected with 4-pentanoate develop signs of acute encephalopathy, as evidenced by excitability followed by lethargy, seizure activity, coma, and death. Generally, the animals rapidly become hyperammonemic, have elevated levels of serum transaminases and amino acids, are hypoglycemic, and have fatty infiltration of the liver. The latter two abnormalities occur only in fasted animals, which is believed to reflect pentenoate-dependent inhibition of fatty-acid oxidation ([@CR72]). Rats that are given 4-pentenoate orally do not develop hepatic fat deposits or mitochondrial structural abnormalities ([@CR72]).

The features that most readily distinguish this animal model from human RS are the absence of serum fatty acidemia and the fact that the animals do not experience an antecedent illness.

### Margosa Oil {#Sec12}

Margosa oil (MO), an unrefined fatty acid-rich extract of the seeds of the Neem tree, was used for centuries as an oral home remedy for cough and general malaise throughout many Indo-Malaysian countries ([@CR63]). Concern for its safety arose when it was found that its ingestion produced a syndrome in young children that had many of the features of RS, including severe brain edema, coma, and a high rate of mortality ([@CR64]; [@CR65]). The active component of the oil has not been identified, but there have been suggestions that it may be an organic sulphur compound ([@CR63]) and/or aflatoxins B and G ([@CR65]). ([@CR40]) recently suggested that the toxic effects of MO may involve one or more of the oil's long- or medium-chain fatty acids and/or the mitochondrial toxins nimbin or nimbiol. The unrefined oil is not available legally on a commercial basis, which restricts its widespread use for an animal model.

Sinniah and coworkers have studied the MO model of RS most extensively in the rat ([@CR66]; [@CR40]), although their initial studies were carried out with mice. In the former, male Sprague-Dawley rats (250 g) are given two ip injections of either corn oil (5 mL/kg) or MO (5 mL/kg), one at time 0, and the second 15 h later. This schedule was set up to mimic the sequence of events associated with development of Reye's-like Syndrome in children following ingestion of the oil. The animals are killed by cervical dislocation 18--20 h after the last injection.

Within 2 h of the first injection, the MO-treated animals exhibit tachypnea and lethargy. Just prior to the second dose, they become hyperreactive to a sudden noise, and shortly after they develop florid neurological signs, including hyporeactivity, coma, and seizures. However, there is no evidence of structural damage or cerebral edema, as judged by a normal brain water content. Serum analyses indicate hyperammonemia, hypoglycemia, and elevated aspartate and alanine transaminase activities. There is no indication in the literature as to whether MO alters serum free fatty acid levels or amino acid profiles. Microvesicular fat droplets are present in the liver and kidney, but not in the brain. There is no evidence of necrosis or inflammation in the liver; however, hepatic mitochondria are swollen, with loss of matrix, cristae, and dense bodies, and liver glycogen is depleted. Of the liver enzyme activities studied (monoamine oxidase, glutamate dehydrogenase, catalase, glucose-6-phosphate dehydrogenase, and lactate dehydrogenase), only catalase was reduced significantly. The results of recent in vitro studies indicate that mitochondrial oxidative phosphorylation is uncoupled by MO, that Stage 4 respiration is increased, whereas the respiratory control ratio is decreased, and that mitochondrial ATP content is reduced ([@CR40]).

The two features of the MO model of RS that appear to be inconsistent with the human disease are the absence of cerebral edema (even though encephalopathy is present) and the relative lack of effect on hepatic mitochondrial activities.

Metabolic Toxin Models {#Sec13}
----------------------

Another approach that has been used to develop animal models for RS has been to bypass the "triggering insult" step and to expose the animals to metabolites that are purported to be the underlying causes of the encephalopathy. Octanoic acid and polyunsaturated fatty acids are the two metabolites that have been studied most extensively.

### Octanoic Acid {#Sec14}

Octanoic acid (C~8~) is an eight-carbon, saturated fatty acid that is one of the metabolites formed during beta oxidation of longchain fatty acids. Based on observations that levels of octanoate are significantly elevated in some children with RS ([@CR43]; [@CR75]; [@CR50]), Trauner and colleagues established a model in which they infuse the fatty acid into adult rabbits ([@CR76]; [@CR77], [@CR78]).

Male 2-kg rabbits are anesthetized with sodium pento-barbitol (30--50 mg/kg) and catheters are placed in the carotid artery and ear veins. When the animals wake up and their vital signs are stabilized, sodium octanoate (0.2*M*, pH 7.4) is infused via the ear vein for a 4 h period. During this time, blood is drawn hourly, and vital signs (heart and respiratory rates, blood pressure, electroencephalogram) are monitored continuously. The rabbits are killed after the 4-h infusion by a rapid iv injection of pentobarbitol (100 mg).

During the infusion of octanoic acid, the rabbits hyper-ventilate, develop hypotonia, coma, and papillary dilatation, and approx one-third have convulsions after 1 h of treatment. Serum changes include increases in ammonia (300%), SGOT (143%), lactic acid (183%), and octopamine (300%). Histopathological studies of the liver indicated that the infusion results in micro-vesicular fat accumulation without hepatocellular necrosis or inflammation, and that the only ultrastructural abnormalities are swollen, pale, and pleomorphic mitochondria that have "fluffy" matrices.

Trauner and coworkers did not find any evidence of generalized cerebral edema in the rabbits, although levels of brain octanoate were significantly elevated. However, they did report that there were signs of early cellular damage, including swelling and degeneration of brainstem neurons and occasional swelling of astrocytic foot processes. These investigators have also demonstrated that intracranial pressure is elevated in the animals ([@CR77]).

### Polyunsaturated Fatty Acids {#Sec15}

The rabbit model of ([@CR37]) is based on observations that serum from children with RS contains abnormally high levels of unesterified polyunsaturated fatty acids (PUFA) (Ogborn et al., 1982), and on the theory that the circulating PUFA could be related to the encephalopathy.

In this model, New Zealand White male rabbits (*Oryctolagus cuniculus*, 2--4 kg) are anesthetized (halothane/O~2~) and placed in a prone position on a table with the head flexed over the edge at right angles to the spinal column. With mature animals, a 25 gage, 16 mm needle is inserted into the cisterna magna until CSF fills the needle. Suspensions of the fatty acids (0.1--0.2 mL) are injected using a tuberculin syringe attached to the needle. Following injection, the animals are placed in a head-down position for 1 min, and then placed on a flat surface for observation. For injection, the fatty acids are suspended in normal rabbit serum/ isotonic saline (1/9, v/v) containing 600--1200 μg protein. Kang and coworkers used 11,14-eicosadienoic acid (C20:2ω6) for many of their experiments. In some studies, they administered the bee venom peptide, mellitin, to stimulate phospholipase A~2~ activity and release fatty acids from endogenous lipids.

Increasing degrees of neurological abnormalities develop in a dose-dependent manner consequent to intercisternal administration of free unsaturated fatty acids. Relatively mild, early changes (Level 1) include hyperventilation, lethargy, and diminished spontaneous movement. A second stage (Level 2) involves an increase in the rate and depth of respiration; the animals are very hyperactive, and in some cases, have tonic-clonic movements of the extremities. This behavior is more exaggerated at higher doses (Level 3), and further increases result in convulsions and coma within 10 min after the injection (Level 4). Fatal cases proceed to a state of apnea (Level 5). Kang et al. demonstrated that encephalopathy did not develop with administration of saturated fatty acids, and that the most profound neurological responses were produced by arachidonic (C20:4ω6) and docosahexaenoic (C22:6ω3) acids, two PUFA that are present in high concentrations in the brain. Injection of melittin into the cisterna magna, and infusion of PUFA into the internal carotid artery produced effects similar to those with intercisternally administered PUFA, however, systemic administration of the acids produced only mild hyperventilation. Interestingly, pre-treatment of the rabbits with aspirin reduced the severity of the neurotoxic effects of the PUFA.

Bacterial Endotoxin Model {#Sec16}
-------------------------

One of the most recently developed animal models for RS involves administration of low doses of endotoxin to rats, with or without low doses of aspirin ([@CR81]; [@CR39]). The model is based on observations that serum from RS patients contains elevated levels of these toxins and that these substances stimulate production and release of bioactive compounds (e.g., monokines) that are responsible for the in vivo toxic effects (e.g., activation of lysosomal proteases).

In the model, male Sprague-Dawley rats (250--300 g) are fasted for 12 h, at which time they are given ip injections of either placebo (5% dextrose in water) (controls) or a sublethal dose (0.2 mg/kg) of *E.coli* 0111:B4 lipopolysaccharide (LPS) (Sigma Chemical Co., St. Louis, MO). The animals are fasted for an additional 12 h, at which time they are killed. Blood samples are taken at 0, 12, and 24 h for determination of baseline, preinjection, and final levels of ammonia, fatty acids and transaminase activities.

Although this model has not been extensively characterized, there is evidence that it reproduces several of the hallmark features of RS. Although Yoder et al. report that none of the animals died before completion of the study, they became lethargic, ataxic, and had decreased self-grooming behavior by 4 h post LPS injection. Brain examination indicated an absence of necrosis and inflammation; microscopic and ultrastructural analyses were normal, with the exception of some proliferation of Type II astrocytes in 2/10 animals. Serum analyses indicated that endotoxin administration was associated with significant (approx twofold) elevations in ammonia, free fatty acids, and lactic acid; fasting alone did not affect these parameters. Unlike the situation in RS patients, serum glucose was normal, as was SGOT activity. Examination of the livers indicated that the endotoxin-treated rats had appreciably greater fat deposition than their fasted controls, and that the mitochondria from 6/10 of the LPS animals were pleomorphic, with expanded and disrupted matrices. In some cases, these changes included swollen mitochondrial cristae and proliferation of endoplasmic reticulum The remaining four rats in this treatment group had less prominent mitochondrial damage. Endotoxin treatment also resulted in liver glycogen depletion.

In their more recent studies, ([@CR39]) have added acetylsalicylic acid (ASA, aspirin) to their experimental paradigm. One hour after the injections of either placebo or LPS, half of each of the two groups is given an ip injection of dextrose and the other half receive ip injections of ASA (50 mg/kg). The results of these studies indicate that addition of ASA results in hepatic production of high levels of the unusual acyl-CoA esters and branched-chain amino acid metabolites that have been reported to be present in RS patients. These observations have led to the proposal that one way in which ASA could be involved in RS is by exacerbating endotoxin-dependent production of toxic metabolites.

Virus Models {#Sec17}
------------

### Concentrated Influenza B Virus {#Sec18}

The most widely studied animal model that employs virus alone is that of Davis and coworkers ([@CR15]; [@CR18]; [@CR19]; [@CR79]). In this model, juvenile (3--4-wk-old) BALB/c mice (10--12 g) are injected iv with high concentrations of influenza B virus (Influenza B/ Lee/40, American Type Culture Collection, Rockville, MD). The virus is an egg-adapted strain of influenza B/Lee/40 that is grown in embryonated eggs and concentrated by ultracentrifugation ([@CR15]). It cannot be administered intranasally, since the high concentrations used will produce a fatal pulmonary congestion via this route. In the model, each animal is inoculated once with 6400 hemagglutination units (in 0.5 mL) through a tail vein, Davis and coworkers have added salicylates to the experimental design in some studies ([@CR16]; [@CR79]), and the results of these are referred to in Section 4.5.2.

Thirty six to forty eight h after injection with the concentrated virus, the mice become ataxic and lethargic, have seizures spontaneously or if they are stimulated, and become comatose. Death occurs in 50% of the mice within 1--3 d following inoculation Laboratory findings indicate significant increases in serum ammonia levels and transaminase (SGOT) activity. Cerebrospinal fluid and serum bilirubin are normal ([@CR15]). The investigators report that serum free fatty acids are elevated and glucose may be reduced, but no data are given ([@CR18]). There is an accumulation of microvesicular fat droplets in the liver, but one of the most significant features is that few, if any, changes are seen in hepatic mitochondrial structure. Injection of the virus results in a 60% inhibition of \[^14^C\]palmitate oxidation by the isolated mitochondria ([@CR79]). Relatively little has been reported regarding the encephalopathy, other than a suggestion that some of the mice have evidence of mild cerebral edema without inflammation. Recent studies have indicated the presence of viral antigens within brain capillary endothelial cells, which suggests that this is a nonpermissive cerebral infection ([@CR19]).

Several concerns have been raised regarding the Davis model for RS, two of which are the requirement for a very large viral inoculum and the fact that it is administered by an intravenous rather than the natural respiratory route. In terms of the laboratory findings, the major disadvantage of the model is that it does not reproduce the mitochondrial structural changes that are the hallmark of human RS.

### Spontaneously Occurring RS? {#Sec19}

In 1984, Brownstein and colleagues reported that on five separate occasions, a spontaneous, RS-like illness broke out among their colony of Balb/cByJ mice after the animals were exposed to indigenous murine viruses. Intestinal coronavirus was the pathogen most frequently associated with the acute illness. The mice that died following a rapid deterioration in consciousness had many pathologic findings (e.g., fatty steatosis of the liver, swollen mitochondria, elevated serum ammonia) characteristic of RS. Neuropathological assessment by light microscopy indicated that there was a significant increase in the number of astrocytes in specific brain regions, and that these had swollen, pallorous nuclei reminiscent of Alzheimer Type II astrocytosis. These changes are not seen in RS. Under electron microscopy, the cytoplasm of cortical astrocytes was electron lucent and expanded, particularly in the pericapillary end-feet. There was evidence of lipid droplets and membrane-bound vacuoles, and a reduced number of glycogen particles. Astrocytic mitochondria were normal in structure. By contrast, neuronal mitochondria were swollen and contained rarified matrices and disorganized and fragmented cristae. With the exception of the Alzheimer type II astrocytic changes, these findings closely parallel those seen in the acute phase of human RS.

The Brownstein model raised the interesting question as to whether RS is an aberrant but spontaneous response to a viral infection. Unfortunately, it has not been possible to investigate this possibility further, since the investigators have not been able to reproduce the model.

Models Based on Chemical/l/iral Interactions {#Sec20}
--------------------------------------------

### Hyperammonemia and Influenza B {#Sec21}

Deshmukh and coworkers established a ferret model for RS on the basis that this species readily becomes hyperammonemic on an arginine-free (Arg) diet, and is very sensitive to infection by human influenza viruses ([@CR21]). The investigators have shown that the combination of these two treatments produces some of the metabolic disturbances characteristic of human RS, and that the effects are exacerbated when salicylates are added to the regimen ([@CR21], [@CR22]; [@CR23]).

A typical experiment ([@CR23]) involves eight groups of young (8-wk-old) male ferrets (400--450 g) (Marshall Research Animals, Inc., North Rose, NY). On day 1 (10:00 am), groups 1, 4, 5, and 7 are inoculated intranasally under light ether anesthetic with human influenza B (Flu B) virus (Georgia/10179; viral titer, 10^6^ EID~50~ mL; 0.5 mL/naris). Acetylsalicylic acid (ASA, Sigma Chemical Co., St. Louis, MO, 50 mg/kg, twice daily) is given to groups 2, 4, 6, and 7 by feeding tube beginning on the evening of day 1 and continuing through the morning of day 4. On day 3 (1:00 pm) food is removed from all cages, and between 9:00 and 11:00 am on day 4, the control groups are given cat chow, whereas those animals in groups 3, 5, 6, and 7 are fed the Arg diet. The latter diet contains amino acids, vitamins, a salt mixture, carbohydrates, and chicken fat. Arginine is replaced by an isonitrogenous amount of alanine. The animals in group 8 are maintained as controls.

Ferrets infected with human influenza B virus exhibit symptoms consistent with flu, including fever, lethargy, and sneezing. These animals do not become hyperammonemic or encephalopathic, even if salicylate is included in the experimental protocol (*see* Tables 1--4 for data summary). By contrast, ferrets that are fed an Arg diet become hyperactive within 2 h, and then progress rapidly to a comatose state. The encephalopathy is associated with 15--20-fold increases in serum ammonia levels. The encephalopathy and biochemical changes are most pronounced when the animals are given the combined FluB, ASA, and Arg diet treatment. In addition to the abnormalities just described, laboratory investigations indicate increased serum levels of free fatty acids and transaminases, normal bilirubin, increased prothrombin time, decreased liver ornithine and carbamyl transferase activities, and increased liver lipids and CSF levels of ammonia and glutamine. Electron microscopic analysis indicates swollen and pleomorphic liver mitochondria and decreased glycogen ([@CR24]). Recent studies have shown that there is intercellular vacuolization and edema in epithelial cells of the choroid plexus ([@CR55]).

Much of the data obtained in the studies of Deshmukh and coworkers suggest that the common denominator in the ferret model is hyperammonemia, and ([@CR34]) have suggested that it is more representative of extreme hyperammonemia than of RS. However, as Deshmukh et al. have shown, elevations in serum ammonia levels per se (i.e., by administration of jack bean urease) does not produce an encephalopathic state ([@CR21]).

### Salicylate Potentiation of Viral Infections {#Sec22}

Much of the recent publicity surrounding RS has centered around its purported connection with aspirin (acetylsalicylic acid; ASA). Although such a relationship tends to be supported by apparent reductions in the incidence of the disease concomitant with reduced aspirin usage ([@CR36]), a causal relationship between the two has not been firmly established.

Salicylates were suggested to be likely candidates for involvement in RS, based on epidemiological studies and on the basis that ASA intoxication can mimic certain features of the syndrome, including hepatic abnormalities (e.g., acid-base disturbances, increased transaminase levels), hypoglycemia, and severe encephalopathy with cerebral edema ([@CR54]). However, salicylism is not usually associated with the excessive elevations in blood ammonia concentrations that one sees in RS ([@CR25]), or with increased serum amino acid levels ([@CR54]). Moreover, ([@CR14]) have recently reported that unlike the case in RS, hepatic mitochondrial size and number are normal or near-normal in patients with salicylate poisoning.

Several groups of investigators have examined the effects of salicylates in their animal models of RS ([@CR42]; [@CR35]; [@CR21],[@CR22]; [@CR16]; [@CR55]; [@CR79]; [@CR33]). A summary of the results of these studies is presented in [Table 4](#Tab4){ref-type="table"}. Table 4**Effects of Salicylates in Animal Models of Reye's Syndrome**SerumEnzymesEncephalopathyExperimental model↑NH3↑FFAElevated transaminasesFatLiver Mitochondrial abnormalitiesOTCCPSBehavior changesMortality rateReferencesFerretsASA(50 mg/kg, B i.d.,3d)−−+ND^1^→↓−0/5Deshmulch et al,1982,ASA + FluB−−−+ND→→−0/51983ASA + FluB +Arg-diet++++ND↓↓Encephalopathy Hyperammonernia12/16FerretsASA(750 mg/kg, b i.d.,4d)NDND+ ±++↓→Encqhalcpathy (→coma)6/13Linnemann et al.,1979FluBNDND−(+)±↓→Fever (mild)0/11ASA + FluBNDND±+±↓→Encephalopathy (→coma)10/19MiceASANDND−−?→→−−Hug et al, 1981?(500mg/kg/d)EMC virusNDND−±−→↓Encephalopathy−ASA + EMC virusNDND−±±→↓Encephalopathy−MiceASA (300−667 mg/kg)NDND(+)−NDNDND−0/54Davis et al, 1985,FluB (concentrated)++++NDND↓Encephalopathy32/60Trauner etASA + FluBND?++NDNDNDEncephalopathy40/61al.,1988^1^ND, not done or not reported

### Surfactant-Dependent Potentiation of a Virus-Initiated Disease {#Sec23}

In the early 1970s, investigators from our laboratories established a mouse model for RS based on observations that children who developed RS in the Maritime provinces were usually from rural areas in which active forestry spray programs were being carried out ([@CR7]). Initial studies of the effects of exposing young animals to pesticides (and/or vehicle) and then infecting them with virus demonstrated that it was the vehicle, an industrial emulsifier, rather than the pesticide, that was active in potentiating viral lethality ([@CR5]; Taylor et al., 1979). We have now studied chemical potentiation of viral infection using several variations of this basic paradigm. The most recent and most extensively studied is a model in which neonatal mice are exposed dermally to nontoxic amounts of the emulsifier, Toximul MP8, and subsequently infected with sublethal doses of mouse-adapted human influenza B virus (FluB) ([@CR11]; [@CR46], [@CR47]).

The chemical/viral mouse model for RS is set up as shown in [Fig. 1.](#Fig1){ref-type="fig"} Male and female Swiss white mice (Charles River, St. Constant, Quebec) are mated at 12 wk of age in a ratio of 3 females to 1 male. The males are removed from the cages after 1 wk. Pups born on the day in which most births occur are used for the experiment, and this is considered Day 0 of the study. On Day 1, the age-matched pups are counted, pooled, and randomly distributed among the nursing mothers. Animals are housed in sets of 2 mothers with 2 litters (7--8 pups/litter) per cage. The neonates are divided into two groups, one of which is painted abdominally with Eagle's Minimal Essential Medium (MEM), and the other group are painted with a 1% solution (8.9 mg/100 mL MEM) of the industrial surfactant, Toximul MP8 (Tox) (Charles Tennant & Company, Toronto, Canada; Lot 9-30162). For the first 5 d, the mice receive 8.6 + 2.6 mg Tox/d; this dosage is increased to 25.8 + 9.0 mg/d for the last 6 d. In a limited number of our studies, Tox was administered in a single ip injection ([@CR11]). Fig. 1.Experimental protocol mouse model for Reye's Syndrome.

The day after the painting is finished (i.e., Day 12), each of the two groups of mice are further subdivided, with half receiving virus under light ether anesthesia and the other half receiving ether alone. The four experimental groups are MEM, Tox, Virus (FluB), and Tox + FluB.

Mouse-adapted influenza B (Lee) virus was obtained originally from F. Ennis, National Institutes of Health, Bethesda, MD. The starting virus is passed seven times in CFW mice according to ([@CR27]). Briefly, for each passage, five mice are inoculated intranasally under light ether anesthesia with 10 μL of the starting virus. After 48 h, the mice are killed and lungs are removed, weighed, and homogenized with a tissue grinder in Hank's balanced salt solution (HBSS)(10% w/v) containing 2% (w/v) gelatin. After two freeze-thaw cycles, the homogenate is centrifuged at 800*g* for 10 min at 4°C to remove debris. The supernatant is diluted in HBSS, and 0.1 mL aliquots are inoculated into the allantoic cavities of 8-day-old fertilized hen eggs. After 48 h at 37°C, the allantoic fluid is collected, centrifuged (800*g*, 10 min), and stored in 0.5 mL aliquots at -80°C (virus stock). The LD~50~, of the virus is determined by recording the mortality over a 7-day period after inoculating 10--12-d-old mice intranasally with different dilutions of the virus stock. For most experiments, the mice are inoculated with 10 PL of a solution containing 640 HA U/0.5 mL.

In each experiment, a proportion (30--60/experimental group) of the total number of animals (approx 600) are set aside for mortality counts, which are carried out each day. The mortality rates vary from one experiment to another; however, mice given the combined Tox plus virus treatment consistently have a higher mortality rate than those given virus alone ([@CR11]; [@CR46]). The two aspects of this detergent + FluB model that best reflect the human disease are the selective ultrastructural damage to hepatic mitochondria ([@CR11]), and the increases in intracranial pressure (ICP) ([@CR13]). Neither effect is seen in animals exposed to detergent alone; virus infection alone does not affect the mitochondria, although it does produce moderate increases in ICP. The serum changes that are consistent with RS include hyperammonemia (also seen with detergent alone) and a decreased total lipid content (hypopanlipidemia). The livers of the combined-treatment mice show no evidence of inflammation or necrosis, but have significantly reduced levels of ornithine transcarbamylase activity. The features that distinguish this model from the human disease are an apparent lack of increase in serum free fatty acids and an absence of hepatic fat. There are at least two possible explanations for these discrepancies, one of which is that they occur during the earlier periods of the experiment at times when no analyses were done, or (and perhaps more likely) the synergism between the detergent and virus with respect to fat abnormalities is a species-specific phenomenon. Support for the latter of these possibilities comes from observations that there is frequently hepatic fat accumulation when the infecting virus is the native mouse pathogen, encephalomyocarditis (EMC) virus. In the EMC model, which has been studied by our group ([@CR5], [@CR6]) and by others ([@CR35]), the mice are exposed to either Toximul (our studies) or to Atlox 3409 F (ICI America Inc., Wilmington, DE) ([@CR35]), and subsequently inoculated ip with the virus in amounts that are titered to produce a 30--50% mortality rate. Deaths generally occur between 2--4 d following inoculation. In addition to developing fatty liver, the mice treated with EMC and detergent have several other hepatic changes consistent with RS (e.g., mitochondrial structural abnormalities and enzymatic changes).

In addition to concerns that the detergent/FluB mouse model does not produce serum hyperfattyacidemia or fatty steatosis of the liver, there have been questions raised regarding the actual deposition of the detergents (or their catabolic byproducts) in the animal tissues, and regarding the cause of death. We have obtained preliminary data confirming the presence of 1,2-dibromoethane (a derivatized byproduct of Toximul) in mouse and human livers, and in human brain samples ([@CR10]) but we have not done a large number of analyses. An important question is whether death results from the lung infection or whether an encephalopathy is involved. The lungs of the mice are infected, and virus can be recovered from them; however, data concerning CNS involvement have been difficult to obtain from such a small animal. In recent studies in which we measured ICP using a scaled-down method described for cats, we found that the mice treated with detergent plus FluB had significantly elevated values for ICP ([@CR13]). Our present focus is to determine whether there is a relationship between detergent exposure, lipid catabolism, and elevated ICP.

Summary {#Sec24}
=======

The fact that each of the models for RS that have been described to date fails to faithfully duplicate all of the known features of the human disease confirms our appreciation of its tremendous complexity. Three undisputed features of the human disease are: The transient damage to hepatic mitochondria that is best exemplified by the ultrastructural changes;The great increase in catabolism; andThe encephalopathy. In most cases, these appear to be related to a viral illness, although several toxins have been identified that produce a RS-like illness. The overriding questions that remain unanswered are: What is/are the factor(s) that either initiate the disease process or cause a host to respond in an abnormal manner to a viral infection;What are the specific metabolic aberrations, and what is/ are their interrelationships; andIn what sequence and with what time course do they occur?

These issues are certainly complicated by our knowledge that some toxins (both xenobiotic and metabolic) can produce at least some of the abnormalities that are seen in RS, but what is their precise relationship with this disease? In this regard, we are hampered by the fact that we often must derive cause-effect relationships on the basis of empirical measurements of substances whose levels can vary greatly both from one individual to another, and from one time period to another. Finally, in our attempts to mimic the disease in animals, we must appreciate that this may be a species-specific disease, one or more of its components may be species-specific, and/or individual events within the disease process may differ from one species to another. In spite of these numerous considerations, we are slowly gaining valuable insight into the complex and perhaps subtle relationships between abnormal metabolism and a life-threatening encephalopathy.
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